Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06264388 · ClinicalTrials.gov registry record · Phase 2
DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
A Phase 2 study of High Grade Glioma and Anaplastic Astrocytoma, sponsored by Ashish Shah.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT06264388 is a Phase 2 study of High Grade Glioma and Anaplastic Astrocytoma that is actively recruiting participants, run by Ashish Shah. The registered enrollment target is 33 participants, below the 65-participant average among 42 other High Grade Glioma trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06264388, a Phase 2 study of High Grade Glioma and Anaplastic Astrocytoma, is actively recruiting participants, sponsored by Ashish Shah.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if the investigational products, DB107-RRV and DB107-FC, as a combination treatment will shrink high-grade glioma (HGG) in patients with recurrent/progressive, resectable or unresectable disease and increase the time that disease is controlled.
Conditions Studied
Interventions
- DRUG DB107-FC
- DRUG DB107-RRV
Study Locations (1)
Florida
- University of Miami Hospital - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2034-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06264388
The ClinicalTrials.gov registry entry for NCT06264388 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 42 other High Grade Glioma trials with a reported enrollment target (49% lower). The listed sponsor is Ashish Shah, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with High Grade Glioma appearing as the primary indexed condition, and to 2 interventions - of which DB107-FC is the first listed.
NCT06264388 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06264388 about?
NCT06264388 is a clinical study titled "DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma". The purpose of this study is to determine if the investigational products, DB107-RRV and DB107-FC, as a combination treatment will shrink high-grade glioma (HGG) in patients with recurrent/progressive, resectable or unresectable disease and increase the time that disease is controlled.
What is the current status of trial NCT06264388?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2024-05-01. Estimated completion is 2034-05-01.
What conditions does trial NCT06264388 study?
This clinical trial studies the following conditions: High Grade Glioma, Anaplastic Astrocytoma.
What interventions are being tested in trial NCT06264388?
The interventions under investigation include: DB107-FC (DRUG), DB107-RRV (DRUG).
Who is sponsoring clinical trial NCT06264388?
This trial is sponsored by Ashish Shah, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06264388 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
RECRUITING · Phase 2
-
Study of Olutasidenib and Temozolomide in HGG
RECRUITING · Phase 2
-
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
ACTIVE NOT RECRUITING · Phase 2
-
Low Dose Radiation Therapy for Glioblastoma Multiforme
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.